Navigation Links
STALLERGENES: 2008: Strong Performance
Date:3/24/2009

re remarkable that it was achieved against the background of a significant investment phase relating to the rollout of the Stalair(R) program (the Stalair(R) program is the new umbrella marketing name of the range of sublingual desensitization tablets). Net R&D expenditure thus increased by 26% and represent 17.5% of sales.

Net profit increased by 17% to EUR 19.0 million and represented an 11.1% net profit margin.

The financial independence of the Group was maintained. EBITDA (gross cash surplus) grew by 14% to EUR 34.3 million, which was largely sufficient to cover investments (EUR 18.3 million), while at the same time generating, for the eighth year in a row, a positive free cash flow of EUR 4.7 million.

Stallergenes strengthened its already sound balance sheet and as a result looks forward to its expansion with confidence. The net financial debt further declined to EUR 9.6 million and only represents 0.3 times EBITDA and 12% of equity.

The Group's 2008 consolidated financial statements are available from the Group's website: http://www.stallergenes.com .

2009 outlook

As regards the Stalair(R) program, five major phase II/III clinical study results are pending. Three of these are "pivotal" studies that will lead to registrations.

The Group remains prudent to date on providing a sales guidance and expects sales growth of between 8% and 10%.

Investments will remain at a high level, without however calling into question Stallergenes' objective of maintaining an operating profitability in excess of 15% of sales and a positive free cash flow.

Significant recent transactions and events

The marketing authorization of Oralair(R) (grass pollen tablets) in its paediatric indication was delivered on 19 January 2009 by the German agency. Oralair(R) is thus mark
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
6. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
9. BIO 2008: Germany on Cutting Edge in Biomanufacturing
10. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
11. Commencement 2008: Student innovation could improve data storage, magnetic sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... , ... Board: LTUS) ("Lotus" or the "Company") a growing developer ... pharmaceutical,products in the People,s Republic of China ("PRC"), today ... operating entity of Lotus,appointed Mr. Jinzhong HAN to be ...
... ... a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited ... products for pregnant and nursing mothers. , ... Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences ...
... Collaboration to Create Optimized Antibodies Produces First Candidates Which ... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, ... program between YM and the National Research Council ... IntelliMab(TM) technology, the program is designed to generate novel ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
(Date:8/20/2014)... E. Fox, a John and Rebecca Moores Professor of Biology ... a fellow in the International Society for the Study of ... of four members two from the U.S., one from ... 2014. Fellows are elected every three years, and 36 have ... more than 20 countries, the ISSOL includes researchers from disciplines ...
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... know Edward Teller as the "Father of the H-Bomb." To his ... detractors he was evil personified. Between these extremes was the life ... well researched attempt to interpret the enigmatic nature of a great ... beliefs," says G. A. Keyworth, II, science advisor to President Reagan, ...
... LAFAYETTE, Ind. - Greenhouse plant growers can substitute rice ... for an increase in growth regulators, according to a ... often consists of a soilless mix of peat and ... also regularly use plant-growth regulators to ensure consistent and ...
... Laxenburg, Austria 26th October 2010 --,A new assessment ... warming cautions that unless current imbalances in R&D portfolios ... technologies are redressed, greenhouse gas (GHG) emission reduction targets ... considerable costs. The study identifies energy efficiency as ...
Cached Biology News:'Judging Edward Teller' 2'Judging Edward Teller' 3Rice hulls a sustainable drainage option for greenhouse growers 2Changes in energy R&D needed to combat climate change 2Changes in energy R&D needed to combat climate change 3
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... types of yeast two-hybrid studies, including complex interaction studies ... Choice of two bait vectors for maximum flexibility and ... Triple reporter strain NMY51 ensures an ... Complete set of controls: pLexA-p53, pLexA-lamin C and ...
Biology Products: